Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This phase I-II multicenter international trial is designed to study the pharmacokinetics of
meropenem and to characterize the safety profile of meropenem in the treatment of infants ≤
90 days of postnatal age with probable or confirmed bacterial meningitis.